ERBB2 and neoplasm: We next used flow cytometry to assess cell-surface binding capacity across HER2-positive tumor models, including NCI-N87 (high HER2 expression), MCF7 (trastuzumab-resistant), and JIMT-1 (trastuzumab-resistant) cells.